Many people book the appointment already knowing which blood test they want drawn. But in a perimenopause workup, the hormone test most people ask about is often the least informative part of the visit.
For adults aged 45 and older with typical symptoms, the diagnosis is usually a clinical one, based on changes in the menstrual cycle and symptoms such as hot flashes or night sweats. Under age 40, or in certain situations such as after specific gynecologic procedures, hormone testing can play a more important role. Blue Point’s guide to women’s health screenings covers the broader preventive picture.
The hormone test most readers arrive asking for, and the line at age 45
Follicle-stimulating hormone (FSH) is the hormone level most perimenopause blood tests measure. The Office on Women’s Health, updated April 2026, says providers do not usually recommend it without a medical reason because hormone levels fluctuate unpredictably during the transition to menopause.
STRAW +10, the 2012 consensus behind today’s stage criteria, explains that in the late menopausal transition, FSH may sometimes rise into the menopausal range and at other times remain within the range seen during earlier reproductive years.
The answer depends partly on age. At 45 or older with typical symptoms, the diagnosis is usually clinical and FSH testing is often unnecessary. Between ages 40 and 45, a clinician may consider testing. Under age 40, the evaluation may require two samples taken four to six weeks apart. In people using combined hormonal contraception, FSH is generally not the appropriate test for identifying menopause.
No guideline establishes one universal FSH cut-off for perimenopause. Different values in the medical literature refer to different stages of the menopausal transition rather than to one diagnostic threshold.
Age 45 and over, where the diagnosis is a clinical one
NICE’s menopause guideline, updated April 2026, advises clinicians to identify perimenopause without laboratory testing in otherwise healthy people aged 45 or older who have recently developed vasomotor symptoms, such as hot flashes and night sweats, along with changes in the menstrual cycle.
MedlinePlus gives similar guidance, noting that testing usually is not needed after age 45 when the symptoms and history are typical.
That does not mean FSH is never useful after 45. When symptoms are unusual or the cause is unclear, testing may still be considered as part of a broader evaluation.
Under 40, between 40 and 45, and after a hysterectomy
Under age 40, the question shifts from staging perimenopause to evaluating for premature ovarian insufficiency.
NICE recommends diagnosing premature ovarian insufficiency based on symptoms plus elevated FSH on two blood samples taken four to six weeks apart, rather than relying on a single blood test.
Between ages 40 and 45, serum FSH may be considered when symptoms include a change in the menstrual cycle.
After a hysterectomy or endometrial ablation, menstrual bleeding can no longer be used reliably to stage the menopausal transition. In those situations, endocrine markers may become more useful, although testing soon after surgery can sometimes be misleading.
Hormonal contraception moves the test in the opposite direction
Combined hormonal contraception changes how FSH results should be interpreted.
NICE advises against using an FSH blood test to identify menopause in people using combined estrogen and progestogen contraception or high-dose progestogen.
StatPearls also notes that estrogens, androgens and hormonal contraceptives can alter FSH levels. That is why the medication and contraceptive history is an important part of the visit before any hormone testing is ordered.
Thyroid, blood count and the alternatives a workup checks for
The blood work used in a perimenopause evaluation often focuses on other conditions that can produce similar symptoms, rather than trying to confirm perimenopause itself.
Pregnancy testing is an important example. In a reproductive-aged patient with abnormal bleeding or missed periods, a urine or serum pregnancy test may be appropriate.
A complete blood count can also help evaluate for anemia, particularly when periods have become heavier or more prolonged.
Mood and sleep symptoms may need their own evaluation. Midlife sleep disruption is not always caused by night sweats, and symptoms such as fatigue, anxiety, depression, insomnia or restless sleep may require separate assessment.
The thyroid question, and the difference between screening and evaluating
Fatigue, low mood, difficulty concentrating, and changes in energy can occur during perimenopause, but they can also appear with thyroid disease.
The American Thyroid Association notes that these symptoms can have many causes, which is why thyroid disease cannot be diagnosed from symptoms alone.
The distinction between screening and evaluating symptoms matters. The USPSTF has found insufficient evidence to recommend routine thyroid screening for nonpregnant adults without symptoms. That does not apply in the same way when a patient has symptoms that could suggest a thyroid problem.
A symptomatic evaluation commonly includes TSH and free T4, interpreted alongside the rest of the clinical picture.
Heavy cycles, iron, and the test the guideline names
Heavy menstrual bleeding can become more common during the menopausal transition and deserves its own evaluation.
ACOG defines heavy bleeding using features such as bleeding lasting more than seven days, soaking through pads or tampons rapidly, or passing larger clots. Significant blood loss can contribute to iron-deficiency anemia.
NICE recommends a full blood count for women with heavy menstrual bleeding.
If the blood count suggests iron deficiency, additional testing may include serum iron and ferritin levels. Those tests evaluate the consequences of blood loss rather than confirming perimenopause.
Cardiovascular and metabolic risk across this window
The menopause transition also overlaps with a period when cardiovascular and metabolic risk factors may change.
The American Heart Association has described midlife and the menopause transition as an important window for changes in lipids, lipoproteins, and vascular health.
That does not mean perimenopause creates a separate schedule for cholesterol or glucose testing. Screening still depends on age, overall risk, weight, family history, and other health factors.
For example, blood glucose or A1C may be considered based on standard recommendations for diabetes screening, while cholesterol testing is interpreted within the broader cardiovascular risk assessment.
The bleeding patterns that get evaluated on their own account
A perimenopause label should not automatically explain every change in bleeding.
ACOG advises patients to report bleeding or spotting between periods, bleeding after sex, unusually heavy bleeding, bleeding that lasts longer than expected, or any bleeding after menopause.
In patients age 45 or older with abnormal uterine bleeding, additional evaluation may be needed because age becomes an important risk factor for endometrial disease.
Depending on the situation, the next step may include endometrial sampling, transvaginal ultrasound, or referral for gynecologic evaluation.
Those tests are not part of a routine perimenopause blood panel. They are used when the bleeding pattern itself requires investigation.
Tracking a pattern instead of a bad week
Because perimenopause is often diagnosed from patterns over time, tracking symptoms can be more useful than relying on one particularly difficult week.
ACOG recommends keeping track of when periods begin, how long bleeding lasts, and how heavy the flow is across multiple cycles.
The Menopause Society similarly encourages tracking cycle changes and symptoms.
No major guideline requires one particular app, symptom diary, or exact number of cycles. The useful information is the pattern itself.
A seven-day swing and a 60-day gap, and what each one answers
Different clinical systems use different numbers because they are answering different questions.
The STRAW staging system identifies the early menopausal transition partly by a persistent difference of seven days or more between consecutive menstrual cycles. The late menopausal transition may include a period of amenorrhea, or no bleeding, lasting 60 days or longer.
Other definitions focus instead on whether bleeding is considered abnormal.
That is why the same cycle change may be useful for staging perimenopause without automatically meaning that the bleeding pattern is medically abnormal.
The questions this visit does not settle
No guideline gives one universal point at which every patient with perimenopause symptoms should move from primary care to gynecology or a menopause specialist.
For many people, the first evaluation can begin in primary care, where the physician can review menstrual history, symptoms, medications, pregnancy possibility, thyroid function, anemia risk, sleep, mood, and other health conditions.
Referral may become appropriate when the bleeding pattern requires further evaluation, symptoms are difficult to manage, the diagnosis is unclear, or additional gynecologic testing is needed.
Treatment options for perimenopause symptoms do exist, including hormonal and nonhormonal approaches, and the choice depends on the patient’s symptoms, medical history, risk factors, and preferences.
Pregnancy also remains possible during perimenopause because ovulation can still occur. That is why a pregnancy test may remain part of the evaluation when clinically appropriate.
Frequently Asked Questions
Can an at-home FSH test confirm perimenopause?
Not by itself. Home FSH tests measure FSH in urine and may detect an elevated level, but they cannot reliably determine where someone is in the menopausal transition.
Because FSH can fluctuate substantially during perimenopause, one positive result does not establish the diagnosis.
If you have symptoms or an abnormal home result, discussing the pattern with a healthcare provider is more useful than relying on the test alone.
How is perimenopause evaluated if I no longer have periods to track?
After a hysterectomy or endometrial ablation, menstrual bleeding cannot be used in the usual way to stage the menopausal transition.
In those situations, hormone testing and other endocrine markers may become more relevant, although results still need to be interpreted carefully and in context.
The evaluation also depends on symptoms, age, surgical history, medications, and whether the ovaries were removed.
How long does perimenopause usually last?
The Office on Women’s Health states that perimenopause usually begins in the mid to late 40s and lasts an average of about four years before periods stop completely.
However, the transition varies widely. For some people it lasts about two years, while for others it may continue for as long as eight years.
Menopause itself is confirmed after 12 consecutive months without a menstrual period.
Conclusion
A perimenopause workup in primary care usually begins with symptoms, menstrual history, age, medications, and changes over time rather than with a single hormone result. For most people age 45 and older with a typical pattern, perimenopause is primarily a clinical diagnosis.
Blood tests may still be useful when the goal is to rule out other causes of symptoms. Depending on the situation, that may include a pregnancy test, TSH and free T4, a complete blood count, iron studies, or other testing based on the patient’s history.
Bleeding changes also deserve separate attention. Heavy bleeding, bleeding between periods, bleeding after sex, or any bleeding after menopause may require additional evaluation rather than being attributed automatically to perimenopause.
If you are experiencing changes in your cycle, hot flashes, sleep problems, unusual bleeding, or other symptoms that may be related to perimenopause, contact Blue Point Medical Group to schedule an appointment. Our primary care team can review your symptoms, health history, medications, and lab needs and help determine the appropriate next step.
This article is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider for questions about your health or before making changes to your treatment plan.
